高龄ICU新冠患者30天死亡率高于非新冠呼吸衰竭患者
该研究基于VIP2和COVIP研究,纳入80岁及以上急性呼吸衰竭的ICU患者,比较新冠与非新冠患者的特点及30天死亡率,重点关注生命维持治疗的限制(LLST)。共693例新冠患者与1393例非新冠患者比较,新冠患者更年轻、衰弱程度更低、SOFA评分更低,但接受有创机械通气的比例更高,30天生存率更低。按年龄(±2岁)、SOFA评分(±2分)、临床衰弱量表(±1分)、性别和地区1:2匹配后,404例新冠患者与666例非新冠患者配对,新冠患者撤除或不予生命维持治疗更频繁,30天生存率几乎为对照组的一半。作者认为,这一差异是否源于更积极限制治疗决策或COVID-19本身固有更高死亡风险尚不清楚。
要点
- 80岁及以上新冠呼吸衰竭患者30天生存率几乎为非新冠患者的一半。
- 匹配后新冠患者不予或撤除生命维持治疗(LLST)比非新冠患者更频繁。
- 新冠患者更年轻、衰弱程度更低、SOFA评分更低,但接受有创机械通气更频繁。
- 匹配因素包括年龄(±2岁)、SOFA评分(±2分)、临床衰弱量表(±1分)、性别和地区,比例1:2。
- 差异原因不明:可能源于更积极限制治疗的决策,也可能源于COVID-19本身固有更高死亡风险。
适用人群与场景
- 80岁及以上急性呼吸衰竭的ICU患者,来自VIP2和COVIP研究。
研究设计与关键结果
- 研究类型:基于VIP2和COVIP研究的匹配队列分析;共693例新冠患者与1393例非新冠患者比较。
- 新冠患者更年轻、衰弱程度更低、SOFA评分更低,但接受有创机械通气(MV)更频繁,30天生存率更低。
- 按年龄(±2岁)、SOFA评分(±2分)、临床衰弱量表(±1分)、性别和地区以1:2比例匹配后,404例新冠患者与666例非新冠患者配对。
- 匹配后新冠患者不予和撤除生命维持治疗(LST)更频繁,30天生存率几乎为非新冠患者的一半。
证据类型、等级与局限
- 证据类型:基于VIP2和COVIP研究的匹配队列分析。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The number of patients ≥ 80 years admitted into critical care is increasing. Coronavirus disease 2019 (COVID-19) added another challenge for clinical decisions for both admission and limitation of life-sustaining treatments (LLST). We aimed to compare the characteristics and mortality of very old critically ill patients with or without COVID-19 with a focus on LLST.
METHODS: Patients 80 years or older with acute respiratory failure were recruited from the VIP2 and COVIP studies. Baseline patient characteristics, interventions in intensive care unit (ICU) and outcomes (30-day survival) were recorded. COVID patients were matched to non-COVID patients based on the following factors: age (± 2 years), Sequential Organ Failure Assessment (SOFA) score (± 2 points), clinical frailty scale (± 1 point), gender and region on a 1:2 ratio. Specific ICU procedures and LLST were compared between the cohorts by means of cumulative incidence curves taking into account the competing risk of discharge and death.
RESULTS: 693 COVID patients were compared to 1393 non-COVID patients. COVID patients were younger, less frail, less severely ill with lower SOFA score, but were treated more often with invasive mechanical ventilation (MV) and had a lower 30-day survival. 404 COVID patients could be matched to 666 non-COVID patients. For COVID patients, withholding and withdrawing of LST were more frequent than for non-COVID and the 30-day survival was almost half compared to non-COVID patients.
CONCLUSION: Very old COVID patients have a different trajectory than non-COVID patients. Whether this finding is due to a decision policy with more active treatment limitation or to an inherent higher risk of death due to COVID-19 is unclear.
参考来源
- Guidet B, Jung C, Flaatten H, et al. Increased 30-day mortality in very old ICU patients with COVID-19 compared to patients with respiratory failure without COVID-19. Intensive Care Med. 2022. PMID: 35218366. doi:10.1007/s00134-022-06642-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。